Remifentanil, Propofol, and Desflurane — Competitive Intelligence Brief

Remifentanil, Propofol, and Desflurane (Remifentanil, Propofol, and Desflurane) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic combination. Area: Anesthesiology.

marketed General anesthetic combination Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane) Anesthesiology Small molecule

Target snapshot

Remifentanil, Propofol, and Desflurane (Remifentanil, Propofol, and Desflurane) — The Cooper Health System. This is a combination of three anesthetic agents that work together to induce and maintain general anesthesia through different mechanisms: remifentanil provides opioid analgesia, propofol induces sedation via GABA potentiation, and desflurane maintains anesthesia via volatile anesthetic action.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Remifentanil, Propofol, and Desflurane TARGET	Remifentanil, Propofol, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)
Sevoflurane+Propofol	Sevoflurane+Propofol	Huazhong University of Science and Technology	marketed	General anesthetic combination	GABA-A receptor
Remifentanil, Dexmedetomidine, and Desflurane	Remifentanil, Dexmedetomidine, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane)
Anesthesia maintenance , propofol,remifentanil,cisatracurium	Anesthesia maintenance , propofol,remifentanil,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Ketofol as induction agent	Ketofol as induction agent	Fayoum University Hospital	marketed	General anesthetic combination	NMDA receptor antagonist (ketamine) and GABA-A receptor agonist (propofol)
propofol，remifentanil，cis atracurium	propofol，remifentanil，cis atracurium	Tang-Du Hospital	marketed	General anesthetic combination (GABA agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Remifentanil, propofol and citanest	Remifentanil, propofol and citanest	University of Aarhus	marketed	General anesthetic combination	Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic combination class)

1. The Cooper Health System · 2 drugs in this class
2. Fayoum University Hospital · 1 drug in this class
3. Huazhong University of Science and Technology · 1 drug in this class
4. Memorial Sloan Kettering Cancer Center · 1 drug in this class
5. The Cleveland Clinic · 1 drug in this class
6. University of Aarhus · 1 drug in this class